All are true about ESBL except -
Which of the following statements regarding resistance of penicillin in Staphylococcus aureus is false?
The initial origin of new drug resistance genes in bacteria most commonly occurs due to:
Which of the following is NOT a criterion for defining extensively drug-resistant tuberculosis (XDR-TB)?
Antimicrobial combinations are used in all except
Identify the correct 'organism-drug to which it is intrinsically resistant' pair.
What is the mechanism of acute rheumatic fever?
A 40-year-old man presents with a year-long history of oral candidiasis, fever, and diarrhea. Physical examination reveals muscle wasting, with his weight at 70% of normal for his height and age. He has generalized nontender lymphadenopathy but no hepatosplenomegaly. Over the past 3 months, he has developed three irregular, 1- to 2-cm, reddish-purple, nodular skin lesions on his forearm. Laboratory findings show hemoglobin, 12.2 g/dL; hematocrit, 36.5%; MCV, 85 mm3; platelet count, 188,000/mm3; and WBC count, 2460/mm3 with 82% segmented neutrophils, 4% bands, 6% lymphocytes, 6% monocytes, and 2% eosinophils. Infection with which of the following organisms is most likely to produce these findings?
Kaposi sarcoma is caused by:
A 30-year-old man presents with persistent cough, night sweats, low-grade fever, and general malaise. A chest X-ray shows findings consistent with a Ghon complex, and sputum cultures are positive for acid-fast bacilli. Examination of the hilar lymph nodes in this patient would most likely demonstrate which of the following pathologic changes?
Explanation: ***Resistant to carbapenems*** - **ESBL (Extended-Spectrum Beta-Lactamase)**-producing bacteria are typically **susceptible to carbapenems**. Carbapenems are a primary treatment option for serious ESBL infections. - Resistance to carbapenems suggests the presence of other resistance mechanisms, such as **carbapenemases**, not ESBLs. *Classification is based on 3rd generation cephalosporin sensitivity* - ESBLs are specifically defined by their ability to hydrolyze and confer resistance to **extended-spectrum cephalosporins** (e.g., ceftriaxone, ceftazidime) and aztreonam. - This characteristic resistance to third-generation cephalosporins is key to their definition and clinical identification. *Cephalosporin sensitivity testing is required to confirm ESBL* - **Phenotypic confirmatory tests** for ESBLs involve demonstrating increased resistance to an extended-spectrum cephalosporin alone compared to the same cephalosporin combined with a **beta-lactamase inhibitor** like clavulanic acid. - This testing is crucial for accurate detection and guiding appropriate antibiotic therapy. *Ambler classification is based on molecular structure* - The **Ambler classification system** categorizes beta-lactamases into classes A, B, C, and D based on their **amino acid sequence homology** and their active site mechanisms. - This classification helps in understanding the biochemical properties and substrate profiles of different beta-lactamases, including ESBLs.
Explanation: ***Hospital strains predominantly produce a unique type of penicillinase*** - This statement is **false** because hospital strains do not produce a truly "unique type" of **penicillinase** compared to community strains. - **Penicillinase (beta-lactamase)** is a common resistance mechanism found across various *S. aureus* strains, not exclusive to hospital environments. *Methicillin resistance is due to alterations in penicillin-binding proteins (PBPs)* - This statement is **true** as **MRSA** resistance involves the **mecA gene** encoding **PBP2a**. - **PBP2a** has low affinity for **beta-lactam antibiotics**, allowing cell wall synthesis despite antibiotic presence. *Penicillinase production is mediated by plasmids* - This statement is **true** because **penicillinase genes** are typically located on **plasmids**. - **Plasmids** facilitate horizontal transfer of resistance genes between bacterial populations. *Penicillinase production can be transmitted by transduction* - This statement is **true** as **transduction** via **bacteriophages** can transfer resistance genes. - **Plasmid-borne penicillinase genes** can spread through this horizontal gene transfer mechanism.
Explanation: ***Mutation*** - **Random genetic changes** in bacteria can alter drug targets or introduce drug-inactivating enzymes, leading to resistance. - **Spontaneous mutations** in the bacterial genome are the primary source of new resistance genes that did not previously exist in the bacterial population. - While mutations occur at low frequency, they are the fundamental mechanism by which novel resistance traits first arise. *Translation* - This is the process of synthesizing proteins from mRNA; it is a fundamental cellular process and not a cause of drug resistance. - Errors in translation are generally lethal to the cell and do not typically confer specific drug-resistant phenotypes. *Conjugation* - This is a mechanism for **horizontal gene transfer** where bacteria directly transfer genetic material, including resistance genes, via a pilus. - While conjugation is the **most important mechanism for spreading resistance** in clinical settings, it transfers pre-existing resistance genes rather than creating new ones. *Transduction* - This is another form of **horizontal gene transfer** involving bacteriophages (viruses) carrying bacterial genes, including resistance genes, between bacteria. - Similar to conjugation, transduction is a mechanism for the **transfer** of pre-existing resistance genes, not their original creation.
Explanation: ***Fluoroquinolone*** - Resistance to **fluoroquinolone alone** is NOT a criterion for XDR-TB because XDR-TB requires a **baseline of MDR-TB** (resistance to both rifampicin and isoniazid) plus additional resistances. - XDR-TB definition (WHO 2021): **MDR-TB** + resistance to **any fluoroquinolone** + resistance to **at least one Group A drug** (bedaquiline or linezolid). - Fluoroquinolone resistance in isolation does not meet any of these combined criteria. *Isoniazid + Rifampicin + Fluoroquinolone* - This represents **MDR-TB** (rifampicin + isoniazid resistance) plus **fluoroquinolone resistance**. - This is a partial criterion approaching XDR-TB but still requires additional resistance to at least one Group A drug (bedaquiline or linezolid) for complete XDR-TB classification. - However, this combination includes the essential MDR-TB base and fluoroquinolone component. *Isoniazid + Rifampicin + Ethambutol + Fluoroquinolone* - This includes **MDR-TB** (rifampicin + isoniazid), **fluoroquinolone resistance**, and ethambutol (first-line drug). - While ethambutol resistance alone doesn't define XDR-TB, this combination includes the critical MDR-TB and fluoroquinolone components required for XDR-TB classification. - Similar to above, would need Group A drug resistance for complete XDR-TB. *Isoniazid + Rifampicin + Kanamycin* - This represents **MDR-TB** plus resistance to **kanamycin** (a second-line injectable). - Under previous WHO definitions (pre-2021), injectable resistance was part of XDR-TB criteria. - This combination includes the MDR-TB base essential for any XDR-TB classification, though it lacks fluoroquinolone resistance.
Explanation: ***Gonorrhea*** - While **gonorrhea** treatment has evolved to include **dual therapy** (e.g., ceftriaxone + azithromycin), this is primarily for co-treatment of potential Chlamydia co-infection and to combat emerging resistance, given as a **single-session treatment**. - Unlike the other conditions, gonorrhea does not require a **prolonged multi-drug regimen** with true synergy or prevention of resistance development during treatment. - The combination is more about empiric co-coverage and resistance concerns rather than the classic indications for antimicrobial combinations (synergy, preventing resistance emergence during therapy, polymicrobial coverage). - This distinguishes it from conditions requiring extended combination therapy. *Intra-abdominal infections* - Involve **polymicrobial etiology** requiring combination therapy to cover both aerobic (e.g., Enterobacteriaceae) and anaerobic bacteria (e.g., Bacteroides fragilis). - Combination therapy ensures broad-spectrum coverage for mixed infections and prevents treatment failures in complex intra-abdominal sepsis. *Malaria* - **Artemisinin-based combination therapies (ACTs)** are the standard first-line treatment for uncomplicated *Plasmodium falciparum* malaria. - Combination therapy reduces drug resistance risk and improves cure rates by targeting different mechanisms of action against the parasite. *Tuberculosis* - Treatment always involves **multi-drug regimen** (isoniazid, rifampicin, pyrazinamide, ethambutol) to prevent emergence of drug-resistant strains. - Multi-drug therapy is essential because *Mycobacterium tuberculosis* rapidly develops resistance if exposed to single agents during the prolonged treatment course.
Explanation: ***Candida krusei - Fluconazole*** - **Candida krusei** is intrinsically resistant to **fluconazole** due to reduced affinity of its target enzyme, **lanosterol 14-alpha demethylase**, for the drug. - This resistance is a natural characteristic of the species, meaning it is inherent and not acquired through exposure. *Aspergillus fumigatus - Micafungin* - **Aspergillus fumigatus** is generally susceptible to **micafungin**, an **echinocandin drug** that targets fungal cell wall synthesis. - While resistance can develop, it is not an intrinsic characteristic of *A. fumigatus* to micafungin. *Candida albicans - Amphotericin B* - **Candida albicans** is typically susceptible to **amphotericin B**, a polyene antifungal that binds to ergosterol in the fungal cell membrane. - Intrinsic resistance to amphotericin B in *C. albicans* is rare, though acquired resistance can occur. *Aspergillus niger - Voriconazole* - **Aspergillus niger** is usually susceptible to **voriconazole**, a broad-spectrum triazole antifungal. - There is no known intrinsic resistance of *A. niger* to voriconazole.
Explanation: ### Explanation **Correct Answer: A. Cross-reactivity with endogenous antigen** The pathogenesis of Acute Rheumatic Fever (ARF) is based on the concept of **Molecular Mimicry** (Type II Hypersensitivity). Following an infection with **Group A Beta-Hemolytic Streptococci (GABHS)**, the body produces antibodies against the streptococcal **M-protein** [1]. Because the M-protein shares structural homology with human molecules, these antibodies "cross-react" with endogenous antigens [2]. Specifically, they target **cardiac myosin**, sarcolemmal membrane proteins, and valvular glycoproteins, leading to the characteristic inflammatory lesions (Aschoff bodies) in the heart [1]. **Analysis of Incorrect Options:** * **B. Innocent bystander effect:** This refers to tissue damage where healthy cells are destroyed during an immune response against a nearby pathogen (often seen in Type III hypersensitivity or viral infections). ARF is a direct autoimmune attack due to structural similarity, not collateral damage. * **C. Due to toxin secretion:** While streptococci produce toxins (like Streptolysin O or Erythrogenic toxin), these cause direct tissue damage (e.g., Scarlet Fever or Toxic Shock Syndrome) rather than the delayed, immune-mediated multi-system inflammation seen in ARF. * **D. Release of pyrogenic cytokines:** While cytokines mediate the resulting fever and inflammation, they are the *mediators* of the response, not the primary *mechanism* of disease initiation. **High-Yield Clinical Pearls for NEET-PG:** * **Latent Period:** ARF typically occurs 2–3 weeks after streptococcal pharyngitis (never after skin infections like impetigo). * **Jones Criteria:** Diagnosis is clinical, requiring 2 Major or 1 Major + 2 Minor criteria plus evidence of preceding GABHS infection. * **Pathognomonic Feature:** **Aschoff bodies** (granulomatous foci) containing **Anitschkow cells** ("caterpillar cells" with condensed chromatin) [1]. * **Most Common Valve Involved:** Mitral valve (Mitral Regurgitation in acute phase; Mitral Stenosis in chronic phase). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Heart, p. 566. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 65-66.
Explanation: **Explanation:** The clinical presentation is a classic case of **Acquired Immunodeficiency Syndrome (AIDS)** caused by **HIV**. The diagnosis is established through a constellation of findings: 1. **Opportunistic Infection:** Recurrent oral candidiasis in an adult is a major red flag for immunosuppression [1]. 2. **Wasting Syndrome:** Weight loss to 70% of normal (Cachexia) is a WHO clinical stage 4 defining criterion for AIDS [1]. 3. **Kaposi Sarcoma (KS):** The "reddish-purple, nodular skin lesions" are pathognomonic for KS, caused by **HHV-8** in the setting of HIV infection [2]. 4. **Lymphopenia:** The WBC count is 2460/mm³ with only 6% lymphocytes, resulting in an absolute lymphocyte count (ALC) of **147/mm³**. An ALC <1500/mm³ (specifically a CD4+ count <200/mm³) is diagnostic of the profound immunosuppression seen in HIV [3]. **Analysis of Incorrect Options:** * **Hepatitis C Virus:** Primarily causes chronic hepatitis, cirrhosis, or hepatocellular carcinoma. While it can cause cryoglobulinemia, it does not present with opportunistic infections or Kaposi-like lesions. * **Herpes Simplex Virus:** Typically causes vesicular/ulcerative lesions (cold sores or genital herpes). While common in HIV patients, it does not explain the systemic wasting or the nodular vascular tumors. * **Mycobacterium leprae:** Causes Leprosy, characterized by hypopigmented patches, nerve thickening, and skin nodules (in lepromatous leprosy), but not generalized lymphadenopathy, profound lymphopenia, or oral candidiasis. **NEET-PG High-Yield Pearls:** * **Kaposi Sarcoma:** Look for "spindle cells," "slit-like vascular spaces," and "extravasated RBCs" on histology. * **HIV Indicators:** Generalized nontender lymphadenopathy (Persistent Generalized Lymphadenopathy - PGL) is often the earliest clinical sign of HIV [3]. * **CD4+ Thresholds:** Oral Candidiasis (<250-500 cells/mm³); Kaposi Sarcoma (<200 cells/mm³); CMV Retinitis/MAC (<50 cells/mm³). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 260-261. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 261-262. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 259-260.
Explanation: **Explanation:** **Kaposi Sarcoma (KS)** is a low-grade vascular neoplasm caused by **Human Herpesvirus 8 (HHV-8)**, also known as Kaposi Sarcoma-associated Herpesvirus (KSHV) [1]. **Why HHV-8 is the correct answer:** HHV-8 is a gamma-herpesvirus that infects vascular and lymphatic endothelial cells [1]. It carries oncogenes (like the viral G protein-coupled receptor and viral cyclin D) that drive cellular proliferation, inhibit apoptosis, and promote angiogenesis. In the setting of immune deficiency (especially HIV/AIDS), the virus replicates uncontrollably, leading to the characteristic spindle cell proliferation and slit-like vascular spaces filled with red blood cells seen histologically [1]. **Why other options are incorrect:** * **HHV-6:** This virus is the primary cause of **Roseola Infantum** (Exanthem Subitum), characterized by high fever followed by a rash in infants. * **HHV-7:** Similar to HHV-6, it is also associated with Roseola Infantum and pityriasis rosea, but it does not possess the oncogenic potential to cause KS. **High-Yield Clinical Pearls for NEET-PG:** * **Four Clinical Variants:** Classic (older Mediterranean men), Endemic (African), Iatrogenic (transplant-related), and AIDS-associated (most common and aggressive) [1]. * **Histology:** Look for "spindle-shaped cells," "slit-like spaces" containing extravasated RBCs, and "hyaline droplets." * **Markers:** HHV-8 LNA-1 (Latent Nuclear Antigen) is the most specific immunohistochemical marker. * **Associated Malignancy:** HHV-8 is also linked to **Primary Effusion Lymphoma (PEL)** and **Multicentric Castleman Disease** [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 261-262.
Explanation: **Explanation:** The clinical presentation of persistent cough, night sweats, low-grade fever, and acid-fast bacilli (AFB) in sputum, combined with a **Ghon complex** on X-ray, is diagnostic of **Primary Pulmonary Tuberculosis (TB)**. **Why Caseous Necrosis is Correct:** Tuberculosis is the classic example of **caseous necrosis** [2]. This is a form of cell death that combines features of both coagulative and liquefactive necrosis. Microscopically, it appears as a "cheese-like" (caseous), structureless, eosinophilic area of debris surrounded by a granulomatous inflammatory border (epithelioid histiocytes, Langhans giant cells, and lymphocytes) [2]. This process is mediated by a Type IV hypersensitivity reaction where macrophages attempt to wall off the *Mycobacterium tuberculosis* [1]. **Why Other Options are Incorrect:** * **Coagulative Necrosis:** Characterized by the preservation of cell outlines ("ghost cells"). It is typically seen in **ischemic infarction** of solid organs (heart, kidney, spleen), but not the brain. * **Fat Necrosis:** Occurs due to the release of activated lipases (as in **acute pancreatitis**) or trauma to breast tissue, resulting in saponification (chalky white deposits). * **Fibrinoid Necrosis:** Seen in **immune-mediated vascular damage** (e.g., Polyarteritis Nodosa, SLE) or malignant hypertension. It involves the leakage of fibrin into vessel walls, appearing bright pink on H&E stain. **NEET-PG High-Yield Pearls:** * **Ghon Focus:** The initial subpleural lesion (usually mid/lower lobes). * **Ghon Complex:** Ghon focus + involved hilar lymph nodes. * **Ranke Complex:** A calcified Ghon complex (visible on X-ray). * **Stain of Choice:** Ziehl-Neelsen (ZN) stain for Acid-Fast Bacilli. * **Cytokine Key:** **IFN-γ** (Interferon-gamma) is the most critical cytokine for activating macrophages to kill *M. tuberculosis* [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Infectious Diseases, pp. 380-381. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Infectious Diseases, pp. 383-384.
Get full access to all questions, explanations, and performance tracking.
Start For Free